Department of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Medicine (Baltimore). 2021 Dec 10;100(49):e28174. doi: 10.1097/MD.0000000000028174.
Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease which making people difficult to breathe and often accompanied with headache. Acupuncture have been proved the therapeutic effect on headache, but there has been no high-quality evidence on acupuncture for the headache in COVID-19. This study is designed to evaluate the effectiveness and safety of acupuncture for headache in COVID-19.
Randomized controlled trials from December 2019 to July 2021 will be included without restrictions on language or publication date. PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Databases, China National Knowledge Infrastructure, Wanfang database, and VIP database will be searched. Two researchers will independently select studies, extract data and evaluate study quality. Cochrane risk of bias tool for randomized trials will be used to assess the risk of bias of included studies. Statistical analyses will be performed using the Review Manager V.5.3 and stata 14.0.
This study will not involve personal information. Ethical approval will not be required. We will publish the results in a peer-reviewed journal.
CRD42021270722.
新型冠状病毒病（COVID-19）是一种急性呼吸道传染病，使患者呼吸困难，常伴有头痛。针刺已被证明对头痛具有治疗作用，但尚无 COVID-19 头痛针刺的高质量证据。本研究旨在评估针刺治疗 COVID-19 头痛的有效性和安全性。
将纳入 2019 年 12 月至 2021 年 7 月的随机对照试验，不限制语言或出版日期。将检索 PubMed、EMBASE、Cochrane 图书馆、Web of Science、中国生物医学数据库、中国知网、万方数据库和 VIP 数据库。两名研究人员将独立选择研究、提取数据和评估研究质量。将使用 Cochrane 随机试验偏倚风险工具评估纳入研究的偏倚风险。统计分析将使用 Review Manager V.5.3 和 stata 14.0 进行。
本研究不涉及个人信息，无需伦理批准。我们将在同行评议的期刊上发表研究结果。
PROSPERO 临床试验注册号：CRD42021270722。
